Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the
 protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
Not provided
Inclusion Criteria:

 1. Female subjects age 18-60 years

 2. Histologically confirmed HPV-16 or HPV-18 asspcoated CIN2, CIN 2/3 or CIN3 from tissue
 collected less than 10 weeks prior to Vaccination/EP #1 with overall lesion sizes less
 than 50% of the cervix area and no evidence of invasive cancer in any specimen;

 3. Colposcopy is satisfactory based on visualization of the entire squamocolumnar
 junction and the upper limit of the entire aceto-white or suspected CIN disease area;

 4. Healthy subjects as judged by the Investigator based on medical history, PE, and
 normal results for an ECG, CBC, Serum Chemistries, CPK and urinalysis done up to 4
 weeks prior to enrolment;

 5. For women who are not postmenopausal (at least 12 months of nontherapy- induced
 amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to
 remain abstinent or use a highly effective method of contraception during the
 treatment period and throughout Week 36 response evaluation visit.

 6. Able and willing to comply with all study procedures and voluntarily signs informed
 consent form.

 Exclusion Criteria:

 1. Unsatisfactory colposcopy defined as incomplete visualization of the entire
 squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN
 disease area;

 2. Pregnancy or breastfeeding;

 3. Immunosuppression including any concurrent condition requiring the continued use of
 systemic or topical steroids at or near the injection site [deltoid, upper arm]
 (excluding inhaled and eye drop-containing corticosteroids) or the use of
 immunosuppressive agents. All other corticosteroids must be discontinued > 4 weeks
 prior to Day 0 of study vaccine administration; autoimmune disorders, transplant
 recipients;

 4. History of previous therapeutic HPV vaccination (individuals who have been immunized
 with licensed prophylactic HPV vaccines (e.g. Gardasil®, Cervarix®) are not excluded);

 5. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen
 (HBsAg) or human immunodeficiency virus (HIV);

 6. Administration of any blood product within 3 months of enrollment;

 7. Administration of any licensed vaccine within 2 weeks of enrollment (4 weeks for
 measles vaccine);

 8. Participation in a study with an investigational compound or device within 30 days
 prior to signing informed consent;

 9. Cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);

 10. History of seizures (unless seizure free for 5 years);

 11. Tattoos, scars, active lesions/rashes or any implantable leads within 3 cm of the
 intended site of vaccination/EP;

 12. Any electronic medical implants (such as cardiac pacemaker);

 13. Active drug or alcohol use or dependence that, in the opinion of the investigator,
 would interfere with adherence to study requirements;

 14. A tendency for severe haemorrhage following acute trauma;

 15. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
 treatment of either a psychiatric or physical (i.e. infections disease) illness must
 not be enrolled into this study;

 16. Any other conditions judged by the investigator that would limit the evaluation of a
 subject.